Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): A randomized, open-label phase III trial.
2017 ◽
Vol 35
(15_suppl)
◽
pp. LBA9007-LBA9007
◽
Keyword(s):
The full, final text of this abstract will be available at abstracts.asco.org at 7:30 AM (EDT) on Monday, June 5, 2017, and in the Annual Meeting Proceedings online supplement to the June 20, 2017, issue of the Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.
2013 ◽
Vol 31
(15_suppl)
◽
pp. LBA8003-LBA8003
Keyword(s):
Keyword(s):
Keyword(s):
2015 ◽
Vol 10
(6)
◽
pp. 883-889
◽
Keyword(s):
Keyword(s):
2010 ◽
Vol 28
(15_suppl)
◽
pp. 7500-7500
◽
Keyword(s):
2012 ◽
Vol 30
(15_suppl)
◽
pp. LBA7500-LBA7500
◽
Keyword(s):
2012 ◽
Vol 30
(15_suppl)
◽
pp. LBA671-LBA671
◽
Keyword(s):
2013 ◽
Vol 31
(15_suppl)
◽
pp. LBA8002-LBA8002
Keyword(s):